ArticleJournal of current glaucoma practice
Safety and Efficacy of Transscleral Cyclodiode Laser in Advanced Glaucoma: A Retrospective, Single-center Observational Cohort Study.
Article in Journal of current glaucoma practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transscleral diode cyclophotocoagulation for refractory glaucoma: real-world efficacy and safety.International ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims and background: Glaucoma is a leading cause of irreversible blindness worldwide. Its global prevalence is projected to exceed 110 million individuals by 2040 (Tham et al., 2014). In 2020, the disease accounted for an estimated 3.6 million cases of blindness and 4 million cases of moderate to severe visual impairment. Between 3 and 17% of patients develop refractory glaucoma, in which progression continues despite maximal medical and surgical treatment (Saunders et al., 2016). Optimizing management of these patients is essential to reduce the global burden of visual disability. Methods: This was a single-center, observational, retrospective cohort study conducted at York and Scarborough Teaching Hospitals. We included patients with refractory glaucoma treated with a single session of transscleral cyclodiode laser between 2019 and 2023. Baseline demographics, intraocular pressure (IOP), and medication use were recorded. Treatment success was defined as ≥20% reduction in IOP and a final IOP ≤ 21 mm Hg at 12 months posttreatment or cessation of oral antihypotensive medication and/or reduction in the number of topical antiglaucoma drops. Results: A total of 108 patients had cyclodiode laser treatment between 2019 and 2023. A total of 62 eyes from 57 patients were included. The average age of the patient was 71.5 ± 15.8 years. The mean baseline IOP was 36.4 ± 12.4 mm Hg, which significantly reduced to 19.0 ± 9.0 mm Hg at 12 months ( Conclusion: Transscleral cyclodiode laser achieved a 77.4% success rate in reducing IOP ≤ 21 mm Hg and ≥20% reduction. It was an effective and well-tolerated option for managing refractory glaucoma. Clinical significance: This study supports the use of a single session of transscleral cyclodiode laser as a viable standalone treatment for patients with advanced, treatment-resistant glaucoma. Its ability to significantly lower IOP and reduce the need for systemic medications, with a favorable safety profile, makes it especially valuable for elderly and frail patients who are poor candidates for further surgery. How to cite this article: Salari Y, Venugopal D, Sohail T,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.